雄激素受体表达与新疆早发性乳腺癌临床病理特征及预后的关系

doi:10.3760/cma.j.issn.1673422X.2016.09.003

摘要/Abstract

摘要： 【摘要】目的研究雄激素受体（AR）表达与新疆早发性乳腺癌患者（年龄≤35岁）的临床病理特征及预后的关系。方法收集新疆医科大学附属肿瘤医院2010年1月至2012年12月经手术切除的浸润性乳腺癌且年龄≤35岁的标本145例，免疫组织化学方法检测其AR表达情况，回顾性分析其临床病理特征及预后与AR表达之间的关系。结果在新疆早发性乳腺癌中AR阳性表达率为69.0%（100/145），单因素分析结果显示AR表达与神经脉管侵犯（χ2=5.309，P=0.021）及淋巴结转移（χ2=6.073，P=0.014）有关，而与民族（χ2=0.097，P=0.755）、年龄（χ2=0.045，P=0.831）、哺育史（χ2=0.066，P=0.797）、肿瘤家族史（P=0.556）、组织学分级（P=0.469）、肿瘤最大径（χ2=1.006，P=0.605）和临床分期（χ2=4.381，P=0.223）无关。中位随访时间47个月，AR表达与新疆早发性乳腺癌的无瘤生存时间无关（χ2=1.972，P=0.160）。结论AR阳性的早发性乳腺癌更易出现神经脉管侵犯和淋巴结转移，可能对临床淋巴结转移阳性的早发性乳腺癌患者的治疗有一定的指导作用。

关键词: 乳腺肿瘤, 肿瘤分期, 受体, 雌激素, 淋巴结转移

Abstract: 【Abstract】ObjectiveTo study the relationships between androgen receptor (AR) expression and the clinicopathological features and prognosis of young patients (age≤35 years) with earlyonset breast cancer in Xinjiang. MethodsOne hundred and fortyfive young patients (age≤35 years) with invasive breast cancer who underwent surgery in Affiliated Cancer Hospital of of Xinjiang Medical University from January 2010 to December 2012 were collected. The expressions of AR in 145 patiens with earlyonset breast cancer were detected by immunohistochemical method. The relationships between AR expression and the clinicopathological features and prognosis of patients with earlyonset breast cancer were retrospective analysed. ResultsThe positive rate of AR expression of patients with earlyonset breast cancer in Xinjiang was 69.0% (100/145). Single factor analysis showed that AR expression was related with neurovascular invasion (χ2=5.309, P=0.021) and lymph node metastasis (χ2=6.073, P=0.014), but it was not related with ethnicity (χ2=0.097, P=0.755), age (χ2=0.045, P=0.831), feeding history (χ2=0.066, P=0.797), family history of cancer (P=0.556), histological grade (P=0.469), tumor size (χ2=1.006, P=0.605) and clinical stage (χ2=4.381, P=0.223). The median followup time was 47 months. There was no significant difference between AR expression and diseasefree survival of patients with earlyonset breast cancer (χ2=1.972, P=0.160). ConclusionEarlyonset breast cancer patients with AR positive are more likely to appear lymph node metastasis and neurovascular invasion than the patients with AR negative, which has certain guidance means for the treatment of earlyonset breast cancer with lymph node metastasis positive.

Key words: Bresat neoplasms, Neoplasm staging, Receptors, estrogen, Lymph node metastasis

李俊婷, 张银华, 赵峰. 雄激素受体表达与新疆早发性乳腺癌临床病理特征及预后的关系[J]. 国际肿瘤学杂志, 2016, 43(8): 651-654.

LI Jun-Ting, ZHANG Yin-Hua, ZHAO Feng. Relationships between androgen receptor expression and clinicopathological features and prognosis of earlyonset breast cancer in Xinjiang[J]. Journal of International Oncology, 2016, 43(8): 651-654.

参考文献

［1］秦颖, 张同先, 张巍, 等. 青年乳腺癌临床病理特点分子分型及预后分析［J］. 中国肿瘤临床, 2014, 41(4): 231236. DOI: 10.3969/j.issn.10008179.20131636. ［2］王承正, 袁鹏, 杨晗昭, 等. AR在不同类型乳腺癌中的表达及临床意义［J］. 河南医学研究, 2015, 24(8): 5456. DOI: 10.3969/j.issn.1004437X.2015.08.025. ［3］张静, 牛昀, 于琦, 等. AR在不同ER状态乳腺癌中的表达及临床病理意义［J］. 中国肿瘤临床, 2012, 39(3): 131135. DOI: 10.3969/j.issn.10008179.2012.03.003. ［4］ Thike AA, YongZheng Chong L, Cheok PY, et al. Loss of androgen receptor expression predicts early recurrence in triplenegative and basallike breast cancer［J］. Mod Pathol, 2014, 27(3): 352360. DOI: 10.1038/modpathol.2013.145. ［5］ Kach J, Conzen SD, Szmulewitz RZ. Targeting the glucocorticoid receptor in breast and prostate cancers［J］. Sci Transl Med, 2015, 7(305): 305ps19. DOI: 10.1126/scitranslmed.aac7531. ［6］ McNamara KM, Moore NL, Hickey TE, et al. Complexities of androgen receptor signalling in breast cancer［J］. Endocr Relat Cancer, 2014, 21(4): T161181. DOI: 10.1530/ERC140243. ［7］庞华靖. 三阴性乳腺癌与雄激素的相关性研究［J］. 国际检验医学杂志, 2015, 36(3): 331333. DOI: 10.3969/j.issn.16734130.2015.03.019. ［8］ Cohee AA, Adams RN, Johns SA, et al. Longterm fear of recurrence in young breast cancer survivors and partners［J］. Psychooncology, 2015, In press. DOI: 10.1002/pon.4008. ［9］ Mohammadizadeh F, Sajadieh S, Sjjadieh H, et al. Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma［J］. Adv Biomed Res, 2014, 3: 132. DOI: 10.4103/22779175.133260. ［10］ McInerney NM, Miller N, Rowan A, et al. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort［J］. Breast Cancer Res Treat, 2010, 121(1): 203210. DOI: 10.1007/s1054900905409. ［11］ Alshenawy HA. Prevalence of androgen receptors in invasive breast carcinoma and its relation with estrogen receptor, progesterone receptor and Her2/neu expression［J］. J Egypt Natl Canc Inst, 2012, 24(2): 7783. DOI: 10.1016/j.jnci.2012.04.001. ［12］ Wenhui Z, Shuo L, Dabei T, et al. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment［J］. Eur J Endocrinol, 2014, 171(4): 527533. DOI: 10.1530/EJE140278. ［13］ Gong Y, Wei W, Wu Y, et al. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance［J］. Cancer, 2014, 120(12): 17751779. DOI: 10.1002/cncr.28667. ［14］ Sultana A, Idress R, Naqvi ZA, et al. Expression of the androgen receptor, pAkt, and pPTEN in breast cancer and their potential in prognostication［J］. Transl Oncol, 2014, In press. DOI: 10.1016/j.tranon.2014.04.004. ［15］ Pistelli M, Caramanti M, Biscotti T, et al. Androgen receptor expression in early triplenegative breast cancer: clinical significance and prognostic associations［J］. Cancers (Basel), 2014, 6(3): 13511362. DOI: 10.3390/cancers6031351. ［16］ Wang Y, Yang H. RE: androgen receptor expression and outcomes in early breast cancer: a systematic review and metaanalysis［J］. J Natl Cancer Inst, 2015, 107(10): pii: djv241. DOI: 10.1093/jnci/djv241. ［17］ Micello D, Marando A, Sahnane N, et al. Androgen receptor is frequently expressed in HER2positive, ER/PRnegative breast cancers［J］. Virchows Arch, 2010, 457(4): 467476. DOI: 10.1007/s004280100964y.

[1]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[2]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[3]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[6]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[7]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[8]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[9]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[10]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[11]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[12]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[13]	张丽, 向卓, 王强, 毕经旺. CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381.
[14]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.
[15]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.